Roche Holdings' share price has experienced a
decline, amid a
moderate outlook for 2024. However, opinions are divided as some analysts question whether the stock is
undervalued given the company's decent financials, and whether the stock could
rebound to its highs.
Berenberg has reduced its target for Roche's share, linking to market instability. Despite this, Roche's
Weight-Loss drug has shown efficacy in early-stage trials, boosting investor confidence and prompting a rise in share price. Roche's other medical advancements, including Accu-Chek SmartGuide's
CE Mark and the FDA approval of Vabysmo prefilled syringe, have also contributed to positive sentiment. Despite this, the company saw a sales decline and
Morgan Stanley has taken a bearish stance on the stock.
Remix Therapeutics reached a milestone in its collaboration with Roche, providing another bright spot. However, overall investors have unfortunately lost 18% over the last three years. Roche's
Ocrevus Subcutaneous received approval from the European Commission, and the company published positive Phase I Obesity drug data. It is also reported that Roche's cancer drug got a breakthrough therapy designation.
Roche Stocks News Analytics from Wed, 23 Aug 2023 07:00:00 GMT to Fri, 12 Jul 2024 15:30:35 GMT -
Rating 0
- Innovation 7
- Information 8
- Rumor -7
